EPISODE · May 1, 2026 · 21 MIN
Episode 497: Reflections on the capivasertib ODAC
from The Uromigos · host The Uromigos
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.
Embed this episode
NOW PLAYING
Episode 497: Reflections on the capivasertib ODAC
0:00
21:15
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of The Uromigos?
This episode is 21 minutes long.
When was this The Uromigos episode published?
This episode was published on May 1, 2026.
Can I download this The Uromigos episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!